Literature DB >> 22834901

Management of heavy menstrual bleeding in general practice.

Kenneth E Fox1.   

Abstract

BACKGROUND: Heavy menstrual bleeding (HMB) is a common symptom that leads women to seek medical treatment. Sources of HMB are variable; patients may present with obvious uterine pathology, systemic disease, or even localized hemostatic dysregulation that defies clinical measurement. Whereas surgical intervention even in the absence of overt pathology had historically been the most common route of treatment for HMB, an expanding therapeutic armamentarium provides greater options and the possibility of maintaining fertility in affected women. SCOPE: A descriptive literature review was performed to identify relevant articles discussing the management of HMB. The PubMed database was searched using the terms 'heavy menstrual bleeding', 'menorrhagia', 'abnormal uterine bleeding', or 'dysfunctional uterine bleeding' in combination with 'diagnosis', 'treatment', 'management', or 'guidelines'. Results were limited to articles published in English within the past 10 years. Additional statements, consensus documents, and clinical guidelines were located through review of professional society websites.
FINDINGS: For practical purposes, a subjective definition of HMB (i.e., excessive menstrual blood loss that is not tolerated by the patient and adversely affects quality of life) rather than objective measures can be used by the clinician as the basis for further investigation. Standard diagnostic examinations and initiation of therapy are well within the purview of the general practitioner. A wide variety of medical therapy options are available, although few treatments are specifically indicated for the management of HMB. The approval of tranexamic acid in the United States specifically for the treatment of HMB is a recent development that provides practitioners with an effective, noncontraceptive alternative medical therapy. For women without evidence of uterine pathology, invasive/surgical procedures are generally considered as a second-line treatment option.
CONCLUSIONS: Given the breadth of available medical and surgical treatment choices, identifying a suitable therapeutic strategy should be feasible for all patients, even in this highly heterogeneous population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22834901     DOI: 10.1185/03007995.2012.716030

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

Review 1.  Antifibrinolytics for heavy menstrual bleeding.

Authors:  Alison C Bryant-Smith; Anne Lethaby; Cindy Farquhar; Martha Hickey
Journal:  Cochrane Database Syst Rev       Date:  2018-04-15

2.  Cost effectiveness of endometrial ablation with the NovaSure(®) system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and Medicaid payer perspectives.

Authors:  Jeffrey D Miller; Gregory M Lenhart; Machaon M Bonafede; Cindy M Basinski; Andrea S Lukes; Kathleen A Troeger
Journal:  Int J Womens Health       Date:  2015-01-06

3.  Cost-Effectiveness of Global Endometrial Ablation vs. Hysterectomy for Treatment of Abnormal Uterine Bleeding: US Commercial and Medicaid Payer Perspectives.

Authors:  Jeffrey D Miller; Gregory M Lenhart; Machaon M Bonafede; Andrea S Lukes; Shannon K Laughlin-Tommaso
Journal:  Popul Health Manag       Date:  2015-02-25       Impact factor: 2.459

4.  Radiofrequency-induced endometrial ablation for the treatment of postpartum hemorrhage after vaginal delivery: Case report.

Authors:  Zhang Wangping; Wu Hanbing
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.